Xenetic Biosciences, Inc.
XBIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immuno-oncology technologies, including a proprietary DNase program targeting NETs for difficult-to-treat cancers, with no approved drug candidates to date.
Key risk: No approved products
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immuno-oncology technologies, including a proprietary DNase program targeting NETs for difficult-to-treat cancers, with no approved drug candidates to date.
- Xenetic is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers [sec_mda · as of 2026-03-12].
- Its proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting NETs involved in cancer progression [sec_mda · as of 2026-03-12].
- The company is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors [sec_mda · as of 2026-03-12].
- As of June 30, 2026, Xenetic reported cash & equivalents of $6.5M, total revenue of $0.7M, net income of -$0.9M, and shareholders' equity of $6.0M [sec].
- To date, none of the company's drug candidates have received regulatory marketing authorization or approval in the U.S. by the FDA or in any other countries [sec_mda · as of 2026-08-06].
What works
- Xenetic's proprietary DNase technology targets NETs, which are involved in cancer progression, potentially improving outcomes of existing immunotherapies [sec_mda · as of 2026-03-12].
- The company is receiving ongoing royalties pursuant to a license of its legacy PolyXen technology, providing a recurring revenue stream [sec_mda · as of 2026-08-06].
- Xenetic collaborates with biotechnology and pharmaceutical industry partners to develop next-generation biologic drugs with improved pharmacological properties [sec_mda · as of 2026-08-06].
What to weigh
- None of Xenetic's drug candidates have received regulatory marketing authorization or approval in the U.S. or any other country, indicating a high-risk development stage [sec_mda · as of 2026-08-06].
- The company continues to commit significant resources to research and development activities, with no guarantee of future commercialization success [sec_mda · as of 2026-08-06].
- Xenetic reported a net loss of $0.9M for the period ending June 30, 2026, reflecting ongoing operating losses [sec].
- The company may need to raise additional working capital to fund its operations and development programs, as noted in risk factors [sec_mda · as of 2025-08-12].
From the filings
Quoted directly from source documents.
Xenetic is focused on immuno-oncology and DNase technology targeting NETs.
“We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. Our proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting NETs, which are involved in cancer progression.”
SEC MD&A · March 12, 2026
No drug candidates have received regulatory approval.
“To date, none of our drug candidates have received regulatory marketing authorization or approval in the U.S. by the Food and Drug Administration nor in any other countries or territories by any applicable agencies.”
SEC MD&A · August 6, 2026
Xenetic is advancing its systemic DNase program for pancreatic carcinoma and solid tumors.
“We are currently focused on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.”
SEC MD&A · March 12, 2026
Risks & what to watch (4)›
Key risks
- No approved products — None of Xenetic's drug candidates have received regulatory approval in the U.S. or elsewhere, posing a high risk of development failure [sec_mda · as of 2026-08-06].
- Ongoing net losses — Xenetic reported a net loss of $0.9M for the period ending June 30, 2026, indicating continued operating losses [sec].
- Need for additional capital — The company may need to raise additional working capital to fund operations and development, as highlighted in risk factors [sec_mda · as of 2025-08-12].
- Dependence on DNase technology — Failure to realize the anticipated potential of the DNase technology could materially impact the company's prospects [sec_mda · as of 2025-08-12].
What to watch
- Progress of the systemic DNase program into clinical trials for pancreatic carcinoma and solid tumors [sec_mda · as of 2026-03-12].
- Any updates on regulatory interactions or approvals for Xenetic's drug candidates [sec_mda · as of 2026-08-06].
- Changes in cash position and any additional financing activities to support operations [sec].
- Royalty revenue from the legacy PolyXen technology license and its impact on financial results [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Xenetic Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xenetic Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
22.4 months
D/E 0.15 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$462K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 137,440 | $368K |
| geode capital management, llc | 21,441 | $57K |
| vanguard capital management llc | 13,462 | $36K |
| jtc employer solutions trustee ltd | 2,700 | $7 |
Short Interest
as of May 22, 2026- % of float
- 0.3%
- Days to cover
- 0.5
- Shares short
- 7,266
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XBIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xenetic Biosciences, Inc.?
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immuno-oncology technologies, including a proprietary DNase program targeting NETs for difficult-to-treat cancers, with no approved drug candidates to date.
Who is the CEO of Xenetic Biosciences, Inc.?
Mr. James F. Parslow is the chief executive officer of Xenetic Biosciences, Inc. (XBIO).
Where is Xenetic Biosciences, Inc. headquartered?
Xenetic Biosciences, Inc. (XBIO) is headquartered in Framingham, MA, United States.
What therapeutic areas does Xenetic Biosciences, Inc. focus on?
Xenetic Biosciences, Inc. develops therapies across Oncology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.